EORTC-26091-BTG

Back to Clinical Trials Database

Randomized trial assessing the significance of Bevacizumab in recurrent grade II and Grade III gliomas. The TAVAREC trial.

Study documentation

Trial Status	All trial activities ended
Dates	Date of activation: 02-Feb-2011 Date Step1 close: 31-Jul-2015
Data management at EORTC	Yes
Design	Phase 2 Randomized open label
Targeted Sample size	EORTC Groups: 144 - All Groups: 144
Treatment	Drug, Drug Bevacizumab, Temozolomide
Study Staff	Martin J. van den Bent (Study Coordinator) , Erasmus MC, Rotterdam Thierry Gorlia (Statistician) , EORTC Headquarters, Brussels Sara Meloen (Pharmacovigilance Manager) , EORTC Headquarters, Brussels Nabila Sebti (Data Manager) , EORTC Headquarters, Brussels Tina Verschuere (Senior Clinical Operations Manager) , EORTC Headquarters, Brussels
Type of cancer	Brain
Participating groups	EORTC Brain Tumor Group
Recruiting centers	APHP Sorbonne Univ - Hopital la Pitie-Salpetriere (PARIS, France) AUSL Bologna - Ospedale Bellaria (Bologna, Italy) Academisch Ziekenhuis Maastricht (Maastricht, Netherlands) CHRU de Lille (LILLE CEDEX, France) CHU Lyon - Hopital neurologique Pierre Wertheimer (BRON CEDEX, France) CHU de Nice - Hopital Pasteur (NICE, France) Centre Eugene Marquis (RENNES CEDEX, France) Centre Hospitalier Universitaire Vaudois - Lausanne (Lausanne, Switzerland) Erasmus MC (Rotterdam, Netherlands) Gustave Roussy (VILLEJUIF CEDEX, France) Haaglanden MC - locatie Antoniushove ( Leidschendam, Netherlands) Hopital de La Timone (APHM) (MARSEILLE, France) Imperial College Healthcare NHS Trust - Charing Cross Hospital (London, United Kingdom) Institut de Cancerologie Strasbourg Europe (formar Paul Strauss) (Strasbourg, France) Institut de Cancerologie de l’Ouest (ICO) - Saint Herblain (Saint Herblain CEDEX, France) Kepler University Hospital - Neuromed campus (Linz, Austria) Leeds Teaching Hospitals NHS Trust - St. James's University Hospital (Leeds, United Kingdom) NHS Greater Glasgow and Clyde - Beatson West of Scotland Cancer Centre - Gartnavel General Hospital (Glasgow, United Kingdom) NHS Lothian - Western General Hospital (Edinburgh, United Kingdom) NHS Tayside - Ninewells Hospital (Dundee, Scotland, United Kingdom) Newcastle Hospitals NHS Trust - Freeman Hospital, Northern Centre For Cancer Care (Newcastle upon Tyne, United Kingdom) Nottingham University Hospitals NHS Trust - City Hospital (Nottingham, United Kingdom) Radboud University Medical Center Nijmegen (Nijmegen, Netherlands) Rambam Health Care Campus, Oncology Institute (Haifa, Israel) Royal Marsden Hospital - Sutton, Surrey (Surrey, United Kingdom) Tel Aviv Sourasky Medical Center (Tel Aviv, Israel) The Christie NHS Foundation Trust (Manchester, United Kingdom) U.Z. Leuven - Campus Gasthuisberg (Leuven, Belgium) UMC-Academisch Ziekenhuis Utrecht (Utrecht, Netherlands) UniversitaetsKlinikum Heidelberg - Head Hospital (Heidelberg, Germany) UniversitaetsSpital Zurich (Zurich, Switzerland) Universitaetsklinikum - Essen (Essen, Germany) Universitaetsklinikum Bonn (Bonn, Germany) Universitaetsklinikum Regensburg (Regensburg, Germany) Universitaetsklinikum Wien - AKH unikliniken (Vienna, Austria) Universitair Ziekenhuis Brussel (Brussels, Belgium) University College Hospital (London, United Kingdom) University Hospital Frankfurt- Goethe University (Frankfurt Am Main, Germany) University Hospitals Bristol NHS Foundation Trust - Bristol Haematology And Oncology Centre (Bristol, United Kingdom) University Medical Center Groningen (Groningen, Netherlands)
Protocol summary	http://clinicaltrials.gov/study/NCT01164189
NCT number	NCT01164189
EudraCT	2009-017422-39
Financial Support	Educational Grant